GSC
PDSB icon

Ground Swell Capital’s PDS Biotechnology PDSB Stock Holding History

Ground Swell Capital’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,703
Closed -$11.3K – 160
2025
Q4 		$11.3K Buy
+14,703
New +$13.3K 0.02% 72
2024
Q3 		– Sell
-22,700
Closed -$66.5K – 240
2024
Q2 		$66.5K Buy
+22,700
New +$72.6K 0.05% 97
2021
Q4 		– Sell
-11,517
Closed -$172K – 96
2021
Q3 		$172K Buy
+11,517
New +$144K 0.74% 46

Other funds holding PDSB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ground Swell Capital's PDSB Position: Q1 2026 in Review

Ground Swell Capital sold out of PDS Biotechnology (PDSB) in Q1 2026, closing a stake of 14,703 shares — an estimated $11.3K sold.

Ground Swell Capital first reported a position in PDSB in Q3 2021 and held it in 3 quarters. The position peaked at $172K in Q3 2021. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.

  • Ground Swell Capital reported no remaining PDS Biotechnology position as of Q1 2026 after selling out during the quarter.
  • Ground Swell Capital sold 14,703 PDS Biotechnology shares in Q1 2026, an estimated $11.3K.
  • Ground Swell Capital first reported a position in PDS Biotechnology in Q3 2021 and held it in 3 quarters.
  • Ground Swell Capital's PDS Biotechnology position peaked at $172K in Q3 2021.
  • 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.

Based on Ground Swell Capital's 13F filing for Q1 2026, filed 21 Apr 2026.